Episode 481: What’s Coming Next for Lipoprotein(a) Treatments

This week, Dr. Kahn breaks down a new paper examining the risks and reported side effects of statins—including the surprising finding that placebo alone is linked to many of the same symptoms. He also covers an oral PCSK9 inhibitor currently under study and what it could mean for cholesterol management.

The episode then dives into the latest research on emerging therapies designed to lower lipoprotein(a), including a real-world case study that highlights where this rapidly evolving field is headed. 

Shorter discussions include heart disease at a young age, why so many patients fail to reach blood pressure treatment goals, aspirin use one year after AFib ablation, skeletal muscle as an endothelial stabilizer, and why exercise variety may be one of the most powerful risk reducers we have. 

Thanks to WellBean for sponsoring the show. Save on their delicious bean-based products at wellbean.life with code DrKahn15. 

Dr. Kahn will also be leading a free online seminar on cholesterol on February 17, 2026 at 7 PM EST with Forks Over Knives. Register HERE.